These tumors may well be particularly sensitive to GITR blockade due to the high frequency of GITR-expressing tumor-infiltrating Tregs, particularly in melanoma, NSCLC, and RCC. This evidence concerns the gene TNFRSF18 and renal cell adenocarcinoma.